QS Research · Michael Burry's Scion Capital analyst template · 2006
Edwards Lifesciences Corp (EW)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $107.11 (close 2026-11-16); latest close $101.85 (2026-11-20), -4.9% since the report; figures re-marked at the latest close
Conclusion: WATCH
Conviction low · base case -46% · downside -54% · upside +13%
The market is pricing Edwards as a durable compounder: at $107.11 the $57.54B enterprise value is 8.62x TTM sales of $6.67B and 39.9x TTM EBIT, while the reverse DCF needs only +6.1% revenue growth a year for ten years against +11.5% delivered in the latest fiscal year. That durability claim is why the call is WATCH rather than a directional bet: the franchise earns a 14.4% ROIC against a 6.3% WACC and holds $4.05B net cash, but the price already discounts it. The base case is $54.52, -49.1%, on EV/Sales at 4.09x, the peer median EV/Sales. The downside is $46.34, -56.7%, on the base case's multiple on -15.0% earnings. The upside is $115.12, +7.5%, on +8% sales at today's EV/Sales of 8.62x. The asymmetry is unfavorable, and the peer anchor rests on only three comparables, so conviction is low.
Key numbers
- Share price: $101.85
- Market cap: $58.56B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $6.67B
- EV / EBITDA (TTM): 33.8x
- P/E (TTM): 57.3x
- FCF yield: 2.4%
- Price / book: 5.39x
- Earnings-quality flags (TTM): Impairments -$367.1M (36% of net income)
- P/E, adjusted (TTM): 42.2x
- EV / FCF (TTM): 38.3x
- Revenue growth (latest fiscal year): +11.5%
- ROIC (TTM): 14.4%
- WACC: 6.3%
- Economic profit spread: +8.0 pts
The 15 boxes
- ✓ 1. Long-form business notes
Edwards Lifesciences sells implantable heart-valve devices, not services: in the FY2025 10-K the business is three product groups — TAVR, TMTT and Surgical Structural Heart — with TAVR at 74% of net sales in 2025, TMTT at 9% and surgical tissue valves at 17%. The FY2020 10-K on file described a fourth group, Critical Care (9% of 2020 net sales), which no longer appears among the product groups in the FY2025 description, so the company is now a pure structural-heart story with TAVR as the revenue engine. Revenue rose from $4.39B in FY2020 to $6.07B in FY2025 and $6.67B TTM to 30 Sep 2026, but operating income has not kept pace — $1.26B in FY2025 and $1.44B TTM against gross profit of $4.73B and $5.21B — and the reported FY2024 net income of $4.17B sits far above that year's $1.55B pre-tax income, so it is not a measure of operating profitability. Cash conversion is the stronger number: operating cash flow of $1.60B in FY2025 and $1.72B TTM to 30 Sep 2026 against capex of $260.2M and $292.8M.
- ✓ 2. Competitive advantage
The sources support a procedure-driven franchise advantage, not a quantifiable wide moat: EW is a leading global competitor in each product line with recognizable structural-heart brands and field clinical support, but Medtronic and Abbott are named primary competitors across TAVR, TMTT and Surgical. Revenue and gross profit grew to $6.07B/$4.73B in FY2025 and $6.67B/$5.21B TTM to 2026-09-30, while operating income was $1.26B FY2025 and $1.44B TTM versus $1.69B FY2021. Cash generation is strong at $1.60B operating cash flow FY2025 and $1.72B TTM, but the sources give no market-share, retention or switching-cost numbers.
- ✓ 3. 10-Q takeaways
Q3 2026 sales were $1,715.5 million, up 10.5% from Q3 2025 (11.2% constant currency), led by TMTT +44.3% and TAVR +8.0%; gross margin was 78.5% and adjusted operating margin 30.3%. Management raised FY2026 sales growth guidance to about 11.5%, TMTT sales to $780-$790 million, and adjusted EPS to $2.97-$3.05. Cash was about $3.1 billion with about $600 million of debt, and nine-month buybacks were $696.6 million. One-offs are material: a $174.4 million tax valuation allowance and $220.2 million of impairment charges sit apart from $0.801 adjusted EPS.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.